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Abstract
The epidural route is still considered the gold standard for labour analgesia,
although it is not without serious consequences when incorrect placement goes
unrecognized, e.g. in case of intravascular, intrathecal and subdural placements.
Until now there has not been a viable alternative to epidural analgesia especially
in view of the neonatal outcome and the need for respiratory support when long-
acting opioids are used via the parenteral route. Pethidine and meptazinol are far
from ideal having been described as providing rather sedation than analgesia,
affecting the cardiotocograph (CTG), causing fetal acidosis and having active
metabolites with prolonged half-lives especially in the neonate. Despite these
obvious shortcomings, intramuscular and intravenously administered pethidine
and comparable substances are still frequently used in delivery units. Since the
end of the 90 ths remifentanil administered in a patient-controlled mode (PCA)
had been reported as a useful alternative ...
Document type : Article de périodique (Journal article)
Référence bibliographique
Kranke, Peter ; Girard, Thierry ; Lavand'homme, Patricia ; Melber, Andrea ; Jokinen, Johanna ;
et. al. Must we press on until a young mother dies? Remifentanil patient controlled analgesia in
labour may not be suited as a "poor man's epidural". In: BMC Pregnancy and Childbirth, Vol. 13,
no.1, p. 139 [1-8] (2013)
DOI : 10.1186/1471-2393-13-139
DEBATE Open Access
Must we press on until a young mother dies?
Remifentanil patient controlled analgesia in
labour may not be suited as a “poor man’s
epidural”
Peter Kranke1*, Thierry Girard2, Patricia Lavand’homme3, Andrea Melber4, Johanna Jokinen1, Ralf M Muellenbach1,
Johannes Wirbelauer5 and Arnd Hönig6
Abstract
Background: The epidural route is still considered the gold standard for labour analgesia, although it is not
without serious consequences when incorrect placement goes unrecognized, e.g. in case of intravascular,
intrathecal and subdural placements. Until now there has not been a viable alternative to epidural analgesia
especially in view of the neonatal outcome and the need for respiratory support when long-acting opioids are used
via the parenteral route. Pethidine and meptazinol are far from ideal having been described as providing rather
sedation than analgesia, affecting the cardiotocograph (CTG), causing fetal acidosis and having active metabolites
with prolonged half-lives especially in the neonate. Despite these obvious shortcomings, intramuscular and
intravenously administered pethidine and comparable substances are still frequently used in delivery units.
Since the end of the 90ths remifentanil administered in a patient-controlled mode (PCA) had been reported as a
useful alternative for labour analgesia in those women who either don’t want, can’t have or don’t need epidural
analgesia.
Discussion: In view of the need for conversion to central neuraxial blocks and the analgesic effect remifentanil has
been demonstrated to be superior to pethidine. Despite being less effective in terms of the resulting pain scores,
clinical studies suggest that the satisfaction with analgesia may be comparable to that obtained with epidural
analgesia. Owing to this fact, remifentanil has gained a place in modern labour analgesia in many institutions.
However, the fact that remifentanil may cause harm should not be forgotten when the use of this potent mu-
agonist is considered for the use in labouring women. In the setting of one-to-one midwifery care, appropriate
monitoring and providing that enough experience exists with this potent opioid and the treatment of potential
complications, remifentanil PCA is a useful option in addition to epidural analgesia and other central neuraxial
blocks. Already described serious consequences should remind us not refer to remifentanil PCA as a “poor man’s
epidural” and to safely administer remifentanil with an appropriate indication.
Summary: Therefore, the authors conclude that economic considerations and potential cost-savings in conjunction
with remifentanil PCA may not be appropriate main endpoints when studying this valuable method for labour
analgesia.
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Background
Ideal labour analgesic will provide sustained pain relief
for the time period when the parturient is in need for
analgesia, but is flexible enough to be adjusted to the
varying analgesic requirements throughout the labour
process and wears off quickly, if analgesia is not needed
any more following delivery. Furthermore, the ideal
labour analgesia will have a low incidence of side effects
for the mother and the baby and will be easy to institute
irrespective of the resources and skills available to allow
that all parturients who wish to experience significant
pain relief actually receive effective analgesics. Moreover,
the ideal labour analgesic may depend on the parturient
and the individual preferences as well as expectations
for the birth experience since maximum pain relief may
not always be of utmost importance [1].
According to the guidelines of the American Society of
Anesthesiologists (ASA) and the American College of
Obstetricians and Gynecologists (ACOG), neuraxial anal-
gesia techniques (epidural, spinal, and combined spinal–
epidural) are recommended in labour as “the most flexible,
effective, and least depressing to the central nervous sys-
tem” of the choices available and thus “allowing for an
alert participating woman and an alert neonate” [2].
Similar statements and recommendations exist on na-
tional levels. The recommendation of the German Society
of Anaesthesia and Intensive Care, for instance, states that
central neuraxial regional analgesia and anaesthesia are es-
pecially safe and effective to provide adequate pain relief
in the peripartum period and for anaesthesia during
cesarean section without leading to a relevant impairment
of the vital signs of the newborn [3].
Owing to the fact that “maternal request is a sufficient
medical indication for pain relief during labor”, the
threshold to withhold effective pain relief is considerable
high. This view is supported by the respective ACOG
recommendations stating that: “Labor results in severe
pain for many women. There is no other circumstance
in which it is considered acceptable for a person to ex-
perience untreated severe pain, amenable to safe inter-
vention, while under a physician’s care. In the absence of
a medical contraindication, maternal request is a suffi-
cient medical indication for pain relief during labor” [4].
These remarks are well in line with general statements
on pain relief and represent the spirit of the Declaration
of Montreal of the International Association for the
Study of Pain (IASP), stating “that access to pain man-
agement is a fundamental human right” [5].
Bearing these essentials in mind – access to pain man-
agement as a fundamental human right and maternal re-
quest as a sufficient medical indication for pain relief
during labour – it is self-evident, that for labouring
women who either don’t want, can’t have or don’t (yet)
need epidural analgesia, best suited alternative options
need to be provided in order to ensure that as much as
possible factors, representing the “ideal labour analgesic”
will be met.
The following discussion provides a short overview of
current analgesic techniques available with special refer-
ence to intravenous remifentanil, administered in a pa-
tient controlled manner. Further, suggestions for future
topics of research with the intention to provide more
solid data when and how its use should be recom-
mended to ensure safety for mother and baby as an
utmost clinical and medicolegal goal will be given. In
addition, the discussion should raise awareness that the
anesthesiologist in the delivery suite should not solely
be regarded as a prerequisite to ensure labour analgesia
via the epidural route but is equally important when it
comes to risk assessment of the labouring woman and
to ensure that emergency situations (including emer-
gency cesarean section) can be adequately managed.
Last but not least the article should stimulate instruct-
ive discussions, whether cost-minimization represents a
suitable approach to assess the suitability of alternatives
to central neuraxial labour analgesia, as outlined and
emphasized in a recently published study protocol in
this journal [6].
Discussion
Long-acting parenterally administered opioid analgesics
Many parenterally administered opioid analgesics have
been tested so far in the aim to provide alternatives for
central neuraxial analgesia in the parturient, either for
those parturients who do not wish to receive central
neuraxial analgesia or in settings where methods of cen-
tral neuraxial analgesia are not available or medically
contraindicated.
The advantage of systemic analgesia may be that it’s use
is not restricted to settings where health professionals be-
ing qualified to perform central neuraxial blocks are avail-
able and appropriate monitoring and the ability to cope
with complications cannot be ensured. Unfortunately, des-
pite extensive search for alternative options and long-
lasting experience with various options, real competitive
options to central neuraxial analgesia have not been eluci-
dated so far.
Unlike in the postoperative or acute trauma setting,
where pethidine has not a place any more [7], pethidine
and meptazinol – and to a lesser degree morphine – still
remain popular and widely used options for pain relief
during labour. In view of the overall limited effect and
well-recognized side-effects [8-10] the persisting domin-
ance of these opioid analgesics remains striking. In a
Norwegian survey published in 2009 pethidine was the
most commonly used opioid analgesic, being adminis-
tered in a nurse controlled fashion in 77% of the units
who responded to the survey, while the epidural
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frequency was only 26% [11]. The survey further found
out that “Nurse-administrated analgesia was the method
of choice for all units, either i.v. or intramuscular (i.m.)”.
It was striking that in this survey fifty-eight per cent
reported only i.m. administration, 8% i.v. and 34% both
forms. A survey conducted in Germany only recently
suggested that parenteral opioids remain a popular offer
for women with labour pain [12]. Despite the fact that
all departments responding to the survey provided a 24
h epidural service, “the most commonly used opioids
were pethidine (19%), meptazinol (17%) and piritramide
(16%) for intermittent intravenous/intramuscular admin-
istration” [12]. In case of the use of a PCA device to ad-
minister the analgesic, remifentanil was already the most
popular choice (68%).
It remains not only the choice of the drugs itself, but es-
pecially the route of administration that lacks scientific
evidence and is considered outdated, e.g. in the postopera-
tive period, to cope with acute pain [7]. What is already
common practice in the postoperative care has not
reached the delivery suites yet, with intramuscular route
still being a popular route of administration. Although the
evidence with any of these drugs given intravenously is
much poorer than with the intramuscular route it remains
unchallenged that “The intramuscular route is not
recommended because it is not dependable – the rate of
drug-absorption may vary. Intravenous administration is
more reliable,….” These recommendations also apply to
so-called “low-resource settings”, as the Chapter 17 on
“Pharmacological Management of Pain in Obstetrics” of
the IASP Guide to Pain Management in Low-Resource
Settings points out [13].
The current evidence regarding parenteral opioids for
labour pain is comprehensively summarized in a recent
Cochrane Review that concluded “Parenteral opioids
provide some relief from pain in labour but are associ-
ated with adverse effects. Maternal satisfaction with opi-
oid analgesia was largely unreported but appeared
moderate at best” [10].
More accentuated views are presented in the original
trials that often suggest “that labour pain is not sensitive
to systemically administered morphine or pethidine” and
that “These drugs only cause heavy sedation. It therefore
seems unethical and medically incorrect to meet parturi-
ents' requests for pain relief by giving them sedation.
Considering the well documented negative effects on
newborn infants we also believe systemic pethidine
should be avoided in labour” [8]. Single trials also report
a rather short-lived effect of traditional opioids when
they draw the conclusion that “Every woman receiving
one injection of meptazinol complained of moderate to
severe pain after 2 h; 97% of those receiving one injec-
tion of pethidine were complaining of moderate to se-
vere pain after 2 h” [14].
And in a comparison with meptazinol, once intro-
duced with the expectation to cause lower incidences
of opioid adverse effects, Nel et al. who compared
meptazinol and pethidine in a double-blind randomized
trial with regard to analgesia during the first stage of
labour as early as 1981 stated “… that neither drug is ef-
fective for sustained pain relief, and that there is no ad-
vantage of one over the other” and further remarked
that “The critical reassessment of traditional drugs for
analgesia in labour is suggested” [15].
Inhaled nitrous oxide
In view of the apparent need to have choice in pain relief
and the frequently observed tendency to first opt for less
invasive methods of pain relief, the popularity of inhaled
analgesia is not surprising. The popularity of nitrous
oxide varies from country to country. While it is used by
about 60% of laboring women in the UK and is also fre-
quently used in Australia and the Scandinavian countries
[11-16], it is rarely available as an analgesic option in
Germany or the USA.
In principle, these methods ensure that the mother
stays awake and laryngeal reflexes remain intact. The
fact that inhaled interventions for pain relief are usually
easy to administer with limited preparation time and fast
onset account for their popularity in some countries.
Recently, the existing body of evidence with respect to
nitrous oxide and other inhaled molecules have been
subjected to a systematic review in which the authors
concluded that “Inhaled analgesia appears to be effective
in reducing pain intensity and in giving pain relief in
labour” [17]. However, these conclusions have been
based mainly on the fact that placebo, sham-treatment
or no treatment provided less pain relief compared to ni-
trous oxide (average RR 0.06, 95% CI 0.01 to 0.34, two
studies, 310 women; MD −3.50, 95% CI −3.75 to −3.25,
one study, 509 women). Based on the report of 8 con-
trolled trials and in 8 observational studies another sys-
tematic review had summarized the findings of these
trials in a systematic review slightly different, stating that
“Nitrous oxide is not a potent labor analgesic, but it is
safe for parturient women….” [18].
It goes without saying that even this ‘innocent’, because
less invasive, intervention is associated with more side
effects for women such as nausea (RR 43.10, 95% CI
2.63 to 706.74, one study, 509 women), vomiting (RR
9.05, 95% CI 1.18 to 69.32, two studies, 619 women),
dizziness (RR 113.98, 95% CI 7.09 to 1833.69, one study,
509 women) and drowsiness (RR 77.59, 95% CI 4.80 to
1254.96, one study, 509 women) when compared with
placebo or no treatment [17]. These findings support the
notion, that it cannot be argued that such an interven-
tion should be tried first, with the argument that no
relevant adverse effects will occur. In addition it might
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be important to note that nitrous oxide is a greenhouse
gas and reacts with ozone. More recently there is increas-
ing evidence of neuroapoptosis induced by anesthetic
agents in the developing brain. The role of nitrous oxide
in this context is unclear [19].
In a study hypothesizing that remifentanil would pro-
vide better analgesia during labour than nitrous oxide,
the authors compared intravenous remifentanil in 0.4
μg/kg PCA doses with 1-min infusion and lock-out
times with intermittent inhaled 50% nitrous oxide during
a 20-min study period with a subsequent 20-min wash-
out sequence after each period [20]. The main result
had been that the “median decrease in pain score for
remifentanil was 1.5 and that for nitrous oxide 0.5
(P=0.01)” on a verbal numeric rating scale from 0 to 10.
Furthermore, “the parturients gave better pain relief
scores with remifentanil than with nitrous oxide” with a
median of 2.5 (remifentanil) vs. 0.5 (nitrous oxide), re-
spectively. In contrast to these more beneficial effects
“sedation was reported more often, and SaO2 was
slightly lower during remifentanil administration” Al-
though blinding was ensured, most patients preferred
the analgesia provided by remifentanil to that provided
by nitrous oxide (14 vs 1, out of 15 parturients who
completed the study).
Remifentanil
Remifentanil is available on the market in Europe since
the 90’s. In Germany, being available since 1996, it is li-
censed to supplement general anaesthesia as a μ opioid
agonist or for the use as analgesic in conjunction with
sedation and analgesia on ICU. Although not very popu-
lar in clinical care, its use as analgesic in the postopera-
tive period for the awake and spontaneous breathing
patient is mentioned in the Summary of Product Char-
acteristics (SPC). In this regard a continuous infusion
(start with 0,1 μg/kg/min) is recommended in the SPC,
while the administration of boluses in the spontaneous
breathing patient is “not recommended” according to
the wording of the SPC.
Owing to its unique pharmacokinetic properties with
rapid metabolism by tissue esterase, its use has been
quickly widened out to the use for labour analgesia,
since for the first time in the history of opioid analgesia
provided by the parenteral route “adequate doses of opi-
oid (could be) administered to the mother to achieve
good analgesia, without its accumulation in the fetus”
[21,22] the use of remifentanil has been extended from
patients presenting with (relative) medical contraindica-
tions for neuraxial blockade to patients who refuse epi-
dural analgesia (e.g. due to backache) [23] or to settings,
where neuraxial analgesia is simply not available [24].
Concomitantly, the use of remifentanil gained popular-
ity for the supplementation of a general anaesthesia in
the cardiovascular compromised obstetric patient, e.g.
aortic or valvular disease [25] or patients presenting with
a cardiomyopathy [26].
Until now, the available published evidence suggests that
even the administration of remifentanil immediately be-
fore cord clamping (e.g. at induction of general anaesthe-
sia for cesarean delivery) does not mean that the neonate
is at significantly increased risk to need mask ventilation
or tracheal intubation [27] although the studies looking at
this outcome are limited and the event rate is still very
low, limiting the conclusions that can be drawn. Further-
more, and owing to own experiences, these endpoints are
highly variable with the experience and knowledge of the
neonatal team caring for the newborn in that regard, that
neonatologists knowing the substance and its unique
pharmacokinetic profile tend to be more conservative re-
garding early airway interventions.
These encouraging data lead to the recommendation
of national societies to supplement general anaesthesia
with an adjunct to attenuate the cardiovascular response
to intubation and skin incision in the parturient with
preeclampsia [3].
The use of remifentanil, though not uniformly sup-
ported by all available evidence, gained more and more
popularity and is in routine use in some institutions, not
only in cases where central neuraxial blocks are contra-
indicated [28,29].
The cumulative evidence suggests that compared with
pethidine, its use for labour analgesia is associated with
significantly improved pain relief and satisfaction and is
associated with a significantly decreased conversion rate
to epidural analgesia [30]. Trials comparing intravenous
patient controlled analgesia using remifentanil with epi-
dural analgesia suggest – which is not a surprise – a
more pronounced reduction in pain scores with
neuraxial analgesia [30,31]. When it comes to overall
satisfaction with the analgesic technique, however, the
studies report that “Maternal satisfaction was similar”
[31] or “Patient satisfaction scores during and after de-
livery were similar in both groups” [32].
In view of the neonatal outcome, the available evi-
dence does not suggest a negative effect on the newborn.
This is not surprising, considering the results obtained
in clinical trials where remifentanil had been adminis-
tered immediately prior to cord clamping in conjunction
with general anaesthesia for caesarean section [27].
Clearly, the potential to cause adverse effects as a po-
tent μ-agonist must not be forgotten [33,34] and subse-
quently has raised concerns in view of its use for labour
analgesia and evoked the provocative question used for
this article: “Must we press on until a young mother
dies?” [35]. The fact that labour analgesia is not a li-
censed indication may have further prevented its use in
many institutions so far [36]. Although it has to be
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emphasized – from a medicolegal point of view – that
the lack of an indication (as stated in the SPC) is not a
sufficient justification to withhold treatment. On the
contrary! Knowing that alternative options – may be
even safer or effective – do exist, would necessitate to
inform patients accordingly and use such an interven-
tion irrespective of its indication as stated by the manu-
facturer in the SPC [37-40].
Remifentanil – what we would like to know
Although in the meanwhile new evidence suggests that
remifentanil will have a role to cope with labour pain
[41], any new evidence to support its use and elucidate
pitfalls and shortcomings may be welcome in order to
promote a safe use and not harm the mother or neonate.
This is especially true since, at least so far, there seems
to be little agreement regarding the necessary monitor-
ing during its use in the labour suite [12]. The latter is
true also for other opioids, since these are associated
with decreases in oxygen saturation, sedation and the
need for oxygen administration as well [42].
Persistent pain following labour is an important socio-
economic factor and has been found to be as frequent as
1 in 10 women [43]. On the other hand remifentanil has
shown to possess a potential to cause opioid-induced
hyperalgesia [44]. Therefore, the role of remifentanil
PCIA in persistent and chronic pain following childbirth
should be addressed in subsequent evaluations.
There is an ongoing discussion on the suitability of vari-
ous regimens to administer remifentanil as labour anal-
gesic. While some argue that a continuous background
infusion may be helpful, others argue – in accordance with
recommendations to ensure safety of opioid patient con-
trolled analgesia in the postoperative setting [45] – that the
avoidance of any background infusion may constitute an
essential safety feature of this highly potent μ-opioid in that
respect that any potential respiratory depression associated
with a self-administered bolus should be short-lived.
In view of these recent developments, we were highly
pleased to read the study protocol describing a ran-
domised controlled trial investigating remifentanil pa-
tient controlled analgesia versus epidural analgesia
during labour (RAVEL protocol) [6].
In a multicentre randomized controlled study performed
at various Dutch hospitals the objective of the study “is to
test the hypothesis that remifentanil PCA is as effective as
epidural analgesia with respect to patient satisfaction and
pain appreciation scores with lower costs and possibly
benefit of easier achievement of 24 hours availability of
pain relief for women in labour” [6].
We would like to challenge the assumption that over-
all costs and ease of administration are meaningful and
sensible endpoints in this setting.
There is no doubt, that in principle and taking into
account all costs of an epidural service and providing a
stand-by service with an anesthesia team in general
(contingency costs) costs more than simply providing a
patient suffering from labour pain and requesting for
pain relief with an intravenous PCIA-pump (patient
controlled infusion pump). However, this assumption
neglects the statement which is valid so far, that
remifentanil PCIA should not be viewed as an full sub-
stitute for epidural analgesia and in many institutions
that extensively practice this method of pain relief is
viewed as complementary tool either for those cases
not needing an epidural catheter or other forms of
neuraxial pain relief or before changing to neuraxial
analgesia [23,28,40].
Although it may be acknowledged that in low resource
settings, the availability of remifentanil could attenuate
suffering in conjunction with childbirth experience, this
should not be the leading argument in developed coun-
tries, where standards have been established and birth
rates are declining. In these settings, the primary aim
should be to hold up the established standards in view
of safety and to this aim, anaesthesiologists may contrib-
ute a lot more than simply inserting epidurals [46].
It goes without saying that the indication to prescribe
remifentanil, at least when administered in analgesic
doses necessary to obtain pain relief during labour,
should stay in the hands of personnel having experiences
with the substance and being able to cope with potential
side effects.
Lastly, the obtained outcomes should be subject to a
close quality control program to gain future insights and
ensure that remifentanil retains its valuable place in the
delivery suite.
To our knowledge there is only one published study,
in which remifentanil was administered as a continuous
infusion in a setting where no anaesthetist has been
available. In view of the potential to cause harm [33], we
would also challenge the general assumption, “that the
presence of an anesthetist for this type of analgesia is
not required and that administration of remifentanil is
quicker and less invasive than epidural analgesia” [6]. At
least, this assumption contradicts the SPC in Germany,
where high hurdles are stated in view of the personal
that should be allowed to administer this potent opioid.
We would rather agree with Tveit and colleagues stating
that “Remifentanil intravenous patient-controlled anal-
gesia provides adequate pain relief and high maternal
satisfaction during the first and second stages of labour”.
but also reminded us that “Maternal sedation and re-
spiratory depression may occur,…” and therefore “careful
monitoring is mandatory” [47].
Owing to the fact that cost analyses are highly variable –
consider for instance the performance of a MRI-Scan to
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exclude epidural abscess or hematoma following epidural
analgesia – we would assume that the outcome in terms
of costs may yield any desired values depending on the
models applied.
To our understanding the aim to assess the possible
“benefit of easier achievement of 24 hours availability of
pain relief for women in labour” [6] cannot be answered
since an epidural service needs to be hold available any-
way due to the performed randomization to either the
epidural or the remifentanil PCIA group. Performing
“epidural analgesia according to local protocol” [6] is a
pragmatic design and per se not criticisable. However,
considering the fact that “epidural analgesia” may imply
quite different protocols, we suspect that this may ren-
der the comparison versus remifentanil highly variable
with regard to the outcome “pain appreciation”.
The authors all use this form a labour analgesia and
are convinced that it fits well into the armamentarium
of labour analgesia available so far. More importantly, it
constitutes an alternative for women who either don’t
want, can’t have or don’t (yet) need epidural analgesia or
want to try an alternative option to central neuraxial an-
algesia first. Therefore, clinical trials and observational
data assessing the risk for maternal fever, assessing the
beastfeeding success, drop in oxygen saturation, satisfac-
tion, APGAR values, Neurologic and Adaptive Capacity
Score (NACS) amongst other well-established outcomes
are welcome.
However, the authors are concerned that if the limita-
tions of remifentanil PCA as a potent intervention are
not strictly taken into account and economic reasoning
is overbearing, we may put too much pressure on this
valuable intervention to succeed and thus “press on until
a young mother dies” [35].
John Snow, by royal invitation, used chloroform on
Queen Victoria during the delivery of Prince Leopold on
7th April 1853. At that time, the medical establishment, in
view of the reported side effects, and with an innate re-
sistance to clinical advances, commented in the Lancet
[48]: “Intense astonishment, therefore, has been excited
throughout the profession by the rumour that her Majesty
during her last labour was placed under the influence of
chloroform, an agent which has unquestionably caused in-
stantaneous death in a considerable number of cases.
Doubts on this subject cannot exist”.
These caveats are nicely illustrated by anecdotal evi-
dence about a Mr. Gladstone, who was Prime Minister
at the time of Prince Leopold’s birth. When he visited
the sovereign to discuss affairs of state Gladstone con-
gratulated the Queen on the addition to her family, and
then asked her how she liked Dr Snow’s chloroform.
The Queen replied ‘Very well, Mr Gladstone’. He replied
‘The bishops are not pleased’. ‘Then let the bishops have
the babies Mr. Gladstone’ she replied.
At these times, nobody would have imagined that
labour analgesia would be as self-evident in conjunction
with childbirth as it is in many institutions around the
world today. And remifentanil may be one day as self-
evident in the labour suite as in the perioperative setting
or as pain relief itself during labour and the regimen
may further vary depending on the setting in which it is
used [49]. However, anaesthesiologists should be cau-
tious and concerned with ensuring that such a valuable
method is not discredited with complications occurring
due to the fact that safety standards are not guaranteed
or cost issues dominate the discussion. We should bear
in mind, that remifentanil patient controlled analgesia in
labour so far should not be viewed as a poor man’s epi-
dural requiring less monitoring as compared to epidural
analgesia [50].
Summary
Multiple beneficial effects when compared with conven-
tional opioids contributed to the fact that remifentanil
PCA has already gained a place in modern labour anal-
gesia in many institutions.
However, remifentanil retains its potential to cause
harm also in the labouring women. In the setting of ap-
propriate precautions, such as one-to-one midwifery
care, appropriate monitoring and providing that enough
experience exist with this potent opioid including its side
effects, remifentanil PCA is a useful option in addition
to epidural analgesia and other central neuraxial blocks,
provided that adequate safety precautions are met. Thus,
for various reasons remifentanil should be viewed as
complimentary method to the more potent neuraxial
techniques and not as a “poor man’s epidural”. Cost-
savings may only be realized by reducing vital precau-
tions and thus leading to catastrophic outcomes, with
the risk to cast a damning light on this valuable arma-
mentarium for labour analgesia.
Therefore, the authors conclude that economic consid-
erations and potential cost-savings in conjunction with
remifentanil PCA may not be appropriate endpoints when
studying this valuable method for labour analgesia [51].
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